Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

CONCLUSIONS: PSMA-PET detected any disease in nearly all patients and M1 disease in 55% of patients previously diagnosed with nmCRPC, including subgroups with PSADT ≤10 months and Gleason score ≥8. The value of PSMA-PET imaging for treatment guidance should be tested in future studies.
PMID: 31511295 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 10, 2019 Category: Cancer & Oncology Authors: Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B Tags: Clin Cancer Res Source Type: research